ADA: Diabetes Duo Merck & Pfizer Report Positive PhIII Data For Investigational SGLT-2

Merck & Co. Inc. and Pfizer Inc.'s investigational oral SGLT-2 inhibitor, ertugliflozin, has met its primary endpoints in two Phase III studies in type 2 diabetes patients – now the pair are continuing development with an 8,000 patient cardiovascular (CV) outcomes trial and plan to file the drug in US by the year end.

Data from the VERTIS Mono trial – presented at the 2016 American Diabetes Association conference, held in New Orleans 10-14 June – showed that ertugliflozin as a monotherapy treatment improved glucose control in type 2 diabetics. Patients randomized to ertugliflozin 5mg and 15mg had significantly greater A1C reductions at 26 weeks of 0.99% and 1.16%, respectively, compared with placebo (p<0.001, for both comparisons) – the primary endpoint of the study.

In addition, significantly more patients taking ertugliflozin 5mg and 15mg achieved the A1C treatment goal of less than 7.0% (28.2%...

Welcome to Scrip

Create an account to read this article

More from Clinical Trials

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Memo Therapeutics Plans BK Virus Therapy Phase III Despite Trial Miss

 
• By 

Pointing to data that show a benefit in reducing viral load and the histological signs of the infection, Memo says its drug, potravitug, could become the first therapy to treat BK polyomavirus in kidney transplant recipients.

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

More from R&D

AZ Poised To Bring Self-Administered C5 Inhibitor To Market

 

Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.